OncoMatch/Clinical Trials/NCT05704621
Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance
Is NCT05704621 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies chemotherapy for ovarian cancer.
Treatment: chemotherapy — This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
platinum sensitive, invasive epithelial ovarian-, fallopian tube- or primary peritoneal cancer; Progression-free interval of at least 6 months after end of last platinum- containing therapy
Must have received: PARP inhibitor — maintenance
Progressed during PARP inhibitor maintenance
Cannot have received: chemotherapy
Exception: one prior chemotherapy allowed
More than one prior chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05704621 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages